ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.59 CNY | +0.13% |
|
-0.65% | -18.91% |
| Sales 2024 * | 10.21B 1.41B | Sales 2025 * | 12.72B 1.76B | Capitalization | 8.93B 1.23B |
|---|---|---|---|---|---|
| Net income 2024 * | 463M 63.97M | Net income 2025 * | 725M 100M | EV / Sales 2024 * | 0.87 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.7 x |
| P/E ratio 2024 * |
19.5
x | P/E ratio 2025 * |
12.5
x | Employees | 8,062 |
| Yield 2024 * |
0.26% | Yield 2025 * |
0.26% | Free-Float | 54.72% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.13% | ||
| 1 week | -0.65% | ||
| Current month | -1.81% | ||
| 1 month | -11.33% | ||
| 3 months | -2.44% | ||
| 6 months | -22.47% | ||
| Current year | -18.91% |
1 week
7.42
7.63
1 month
7.428.64
Current year
6.439.84
1 year
6.4311.85
3 years
6.4317.90
5 years
6.4321.97
10 years
6.4327.93
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Qing Yang
CEO | Chief Executive Officer | - | 23-08-30 |
Jia Qiu Du
CHM | Chairman | 50 | 19-05-12 |
Wei Hong Xiao
PSD | President | 56 | 23-10-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shun Bing Yu
CHM | Chairman | 61 | - |
Jia Yi Zhao
BRD | Director/Board Member | 64 | 19-05-12 |
Li Rong Yang
BRD | Director/Board Member | 62 | 19-05-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +4.82% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-12 | 7.59 | +0.13% | 6,952,058 |
| 24-06-11 | 7.58 | +0.53% | 7,853,909 |
| 24-06-07 | 7.54 | +0.67% | 7,585,100 |
| 24-06-06 | 7.49 | -1.32% | 12,352,020 |
| 24-06-05 | 7.59 | -0.65% | 6,879,694 |
End-of-day quote Shanghai S.E., June 11, 2024
More quotes
Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infection drugs, endocrine control drugs, anthelmintic, as well as animal remedies, among others. The Company is also engaged in the sales of drugs manufactured by other companies. The Company distributes its products in domestic markets and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
7.59
CNY
Average target price
7
CNY
Spread / Average Target
-7.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.91% | 1.23B | |
| +48.79% | 780B | |
| +41.76% | 627B | |
| +19.43% | 334B | |
| +7.18% | 296B | |
| +17.60% | 244B | |
| -0.41% | 217B | |
| +11.54% | 214B | |
| +4.53% | 161B | |
| -3.92% | 159B |
- Stock Market
- Equities
- 600267 Stock
